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E-mail address: eayoung@umich.edSummary Background: Numerous interactions between the brainstem locus
coeruleus system and the HPA axis have been shown in experimental animals. This
relationship is less well characterized in humans and little is known about the
influence of psychiatric disorders, which disturb one of these systems, on this
relationship.
Methods: Untreated subjects with pure MDD (nZ13), MDD with comorbid anxiety
disorders (nZ17), and pure anxiety disorders (nZ15) were recruited by advertising.
Age and sex matched control subjects were recruited for each subject with a
psychiatric diagnosis (nZ45). All subjects underwent a social stressor, the Trier
Social Stress Test (TSST), and blood was collected for ACTH assay. These same
subjects also underwent a clonidine challenge study for assessment of growth
hormone release as a marker of tonic noradrenergic activation.
Results: Examining log transformed area under the curve response for each
hormone, a significant negative relationship (simple regression) was observed
between systems in normal subjects. This relationship was preserved in anxiety
subjects. However, both pure depressed and comorbid depressed and anxiety
subjects demonstrated disruption of this relationship.
Conclusions: Under normal circumstances, noradrenergic systems can influence the
magnitude of the HPA axis response to stress. However, in subjects with major
depression, HPA axis activation appears autonomous of noradrenergic influence.
Q 2005 Elsevier Ltd. All rights reserved.1. Introduction
Stress activates a number of systems including the
hypothalamic pituitary adrenal (HPA) axis and
the brain noradrenergic system controlling5 Elsevier Ltd. All rights reserv
4 936 2087; fax: C1 734
u (E.A. Young).autonomic output (Pacak and Palkovits, 2001; Sved
et al., 2002). Both systems have been extensively
studied in depression and anxiety disorders,
although rarely in the same patient. Basic
science data suggest these systems are linked via
corticotropin releasing hormone (CRH) (Pacak and
Palkovits, 2001; Sved et al., 2002). CRH and its
receptors are widely distributed and central injec-
tion of CRH can mimic a generalized stress response
(Dunn and Berridge, 1990). Stress activatesPsychoneuroendocrinology (2005) 30, 807–814
www.elsevier.com/locate/psyneuened.
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neuronal cell bodies are located, and this activation
can involve CRH (Sved et al., 2002; Valentino, 1989;
Aston Jones et al., 1991). CRH-mediated pathways
connect the amygdala and LC (Curtis et al., 2002;
Commons et al., 2003). LC neurons provide stimu-
latory noradrenergic input to the paraventicular
nucleus (PVN); activation of the PVN leads to HPA
axis activation and cortisol secretion (Curtis et al.,
2002; Commons et al., 2003; Plotsky, 1987). Cortisol
inhibits both the HPA axis and LC neurons, but it
stimulates amygdala CRH neurons, which can result
in excessive activation of the amygdala CRH system
in the presence of hypercortisolemia (Mc Ewen,
1995; Makino et al., 1994; Watanabe et al., 1995).
Despite these extensive and important linkages
observed in animals, links between these systems
have been little studied in humans.
In humans, brain noradrenergic activity can be
assessed only indirectly—for example, by measuring
growth hormone (GH) response to an adrenergic
agent like clonidine (Abelson and Cameron, 1994).
GH release is partially controlled by post-synaptic
a2-receptors, and sensitivity of these receptors is
modulated by tonic levels of LC output. GH
response to adrenergic agents thus reflects tonic
levels of noradrenergic outflow from the brain
(Devesa et al., 1990, 1991). A blunted GH response
to clonidine has been reported in both anxiety and
depression (Charney and Heninger, 1986; Nutt,
1989; Uhde et al., 1986; Siever et al., 1982;
Amsterdam et al., 1989; Charney et al., 1982) and
interpreted as evidence for excessive central
noradrenergic activity in these disorders.
Depression is accompanied by HPA axis acti-
vation and reduced sensitivity to negative feed-
back, while the HPA axis in anxiety disorders
appears to be relatively normal (Young et al.,
1991, 1993, 2000, 2004; Abelson and Curtis, 1996).
Anxiety disorders are thought to involve activation
of brain noradrenergic systems (Charney and
Heninger, 1986; Nutt, 1989; Uhde et al., 1986),
but whether this is the case in depression is less
clear (Cameron et al., 2004). Given the complex
linkages between LC and HPA axis described above,
associations between HPA axis and noradrenergic
measures should be expected in clinical studies.
HPA axis activation and GH blunting have in fact
been linked in a primate study (Coplan et al., 2000)
and several human studies have found greater HPA
activation and noradrenergic activation in the same
subjects (Valdivieso et al., 1996; Wong et al., 2000;
Roy et al., 1986, 1988; Rubin et al., 1985; Maes
et al., 1991) although most studies did not report
the correlation, if any, in normal subjects. Very few
studies have utilized probes of both systems inthe same individuals across diagnostic categories.
To further explore system linkages and the impact
of psychiatric disorders on them, we examined both
stress systems in the same individuals, comparing
subjects with an anxiety disorder, with depression,
and with both anxiety and depression to matched
groups of healthy controls. We used clonidine
stimulated GH as an index of chronic noradrenergic
activation, and response to the Trier Social Stress
Test (TSST) to measure HPA axis reactivity.2. Methods
2.1. Subjects
All studies were approved by the University of
Michigan IRB. Subjects gave informed consent for a
‘public speaking task’ and the clonidine adminis-
tration procedure. Subjects with major depression
and anxiety disorders and normal controls were
recruited by advertising from the community. After
initial screening, the SCID-IV was administered by a
trained research nurse, and subjects meeting inclu-
sion/exclusion criteria were recruited into the
study. A ‘pure’ depression group (nZ13) was
composed of subjects who had Major Depressive
Disorder (MDD) and did not meet current or past
DSM-IV criteria for any anxiety disorder. A ‘pure’
anxiety group (nZ15) was composed of subjects who
met DSM-IV criteria for an anxiety disorder (Panic, or
Social Anxiety Disorder), with no current or recent
past depression. Four of the subjects included in this
group had a past episode of major depression, but
these occurred a minimum of 2 years prior to the
study and in all cases the anxiety disorder predated
the depressive episode. A comorbid group (nZ17)
was composed of subjects who met criteria for
either a current anxiety or depressive disorder and
also met criteria currently or within the past 6
months for a disorder from the other category. All 17
actually had both current anxiety and current
depression at time of recruitment into the study.
One patient with panic experienced reduced fre-
quency of attacks after enrollment and prior to
study. Two subjects experience partial improvement
in depressive symptoms such that they no longer met
full criteria for a major depressive episode at the
time of the challenges. All subjects were free of all
medication, including oral contraceptives and over
the counter herbal remedies. Subjects were also
excluded if alcohol intake was greater than seven
drinks per week or if caffeine intake was greater than
two cups of coffee or caffeine containing drinks per
day. Cigarette smokers were excluded. Only five of
Interaction noradrenergic and HPA systems 809the subjects had ever received psychotropic medi-
cations and the most recent exposure in any subject
was 9 months prior to study. The numbers of subjects
in the three psychiatric groups differ from the
previous reports (Young et al., 2004; Cameron
et al., 2004), because not all subjects completed
both challenges. Normal subjects were individually
matched on sex and age and were free of all
psychiatric diagnoses, in themselves and their first-
degree relatives.2.2. Challenge procedures
All subjects participated in both challenges: cloni-
dine infusion with measurement of growth hormone
to assess the noradrenergic system, and the Trier
Social Stress Test (TSST) for measurement of ACTH
and cortisol response to an emotional stressor. The
challenges were carried out in random order on
separate days at least 2 days apart (average 13G12
(SD) days).2.2.1. TSST
At 1430 h on the day of study, subjects reported to a
neuroendocrine study suite at the University of
Michigan Depression Program. They were placed
supine in bed and an intravenous catheter was
inserted for blood drawing. Beginning at 15:00 h,
and continuing until 60 min after task completion,
blood was drawn every 10 min for ACTH and
cortisol. At 15:30 h, subjects were moved to
another room for the TSST, a public speaking task
involving a mock job interview and mental arith-
metic (Kirschbaum et al., 1993; Young et al., 2004).
Following completion of the stress session, subjects
were then allowed to rest quietly for an hour, until
blood sampling was completed.2.2.2. Clonidine stimulated GH
Subjects were admitted to a Clinical Research
Center at 07:30 h and an intravenous catheter for
blood draws and clonidine infusion was inserted
within 30 min. They were kept at bed rest. Starting
at 09:00 h, clonidine (2 mcg/kg) was administered
intravenously over 5 min by infusion pump. Samples
for GH were drawn 30, 15, and 1 min before the
infusion and 15, 30, 60, 90, and 120 min after its
completion. Symptom severity ratings (Hamilton
Depression and Anxiety Rating Scales) were com-
pleted on the day of the study.2.3. Hormone assay
Samples were immediately placed on ice after
being drawn. Those for ACTH and cortisol werecentrifuged within 10 min of collection and those
for GH within 30 min. Plasma was then frozen at K
708 until assay. Subjects and their matched controls
were paired for all assays. Cortisol was assayed
using DPC (Los Angeles, CA) Coat-a-Count kits.
ACTH was assayed using Allegro HS IRMA (Nichols
Diagnostic Institute, San Juan Capistrano, CA).
Inter-assay variability for ACTH was 7.3% and for
cortisol was 5%. GH samples were assayed by the
Nichols IRMA method, with an inter-assay coeffi-
cient of variation of 6.8%.2.4. Statistical analyses
Area under the curve (AUC) was calculated for each
hormone, using trapezoidal approximation after
subtracting a baseline value from each measure.
Since the accommodation period was relatively
short and varied between challenges and recovery
periods were relatively long, we utilized the lowest
level achieved for each hormone during any phase
of the study as that subject’s ‘baseline’. AUCs were
natural log transformed and then subjected to
linear regression analyses, focusing on relationships
between responses to the TSST and responses to
clonidine. Individual matching of normal subjects
to patients controlled for age, sex, and assay
variability, so covariates for these measures were
not utilized. In order to limit the total number of
regression analyses run for this report, we focused
on the two measures which revealed the most
meaningful group differences in the above results:
ACTH response to the TSST and GH response to
clonidine. Challenge order did not affect results of
either challenge and was therefore also ignored in
these analyses.3. Results
Table 1 presents the demographic and clinical data
for all subjects who underwent both challenges.
Results of each challenge have been previously
reported (Young et al., 2004; Cameron et al., 2004)
and will only be briefly summarized here. On the
TSST, subjects with comorbid depression and
anxiety demonstrated an exaggerated ACTH
response to psychosocial challenge, whereas both
pure anxiety and pure depression subjects showed
normal responses. On the clonidine test, the pure
anxiety group demonstrated a blunted GH response
while the pure depressed group demonstrated a
normal response and the comorbid group appeared
intermediate. Tables 2A and B presents the
regression data for clonidine stimulated GH and
Table 1 Characteristics of the depressed (MDD), anxiety and control group.
Pure MDD Comorbid MDD Pure anxiety Controls
Number of subjects 13 17 15 45
Age 28.2G7.7 (SD) 23.2G5.5 25.4G8.5 25.8G7.1
Sex F:M 7:6 13:4 8:7 26:19
Hamilton depression rating 18.3G3.7 (SD) 12.76G6.9 (SD) 3.3G3.4 (SD) 0.5G0.9 (SD)
Hamilton anxiety rating 12.7G3.8 (SD) 12.3G7.2 (SD) 5.8G7 (SD) 0.7G0.7 (SD)
Anxiety diagnoses 0 17 15 0
Panic disorder 0 4 3 0
Social phobia 0 13 12 0
PTSD 0 2a 1a 0
AUC ACTH 133G122 262G308 181G163 196G175(SD)
AUC GH 275G208 238G256 173G146 306G298 (SD)
a Also met criteria for panic disorder (1) and social phobia (1) in comorbid group and social phobia in anxiety group.
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correlation (rZK0.4) between these two systems
in the control subjects (Tables 2A and B, Fig. 1). The
correlation is negative, indicating that a larger
ACTH response to the stressor was associated with a
smaller GH response to clonidine. We examined
whether gender influenced the correlation, but
because of reduced power, only females demon-
strated a significant correlation although the actual
correlation coefficient was very similar for males
and females. (females: rZ0.41, FZ4.72, dfZ1,
pZ0.04; males rZ0.416, FZ3.56, dfZ1, pZ0.07).
While a significant correlation was observed in the
control subjects, the correlation between systems
in the patient group was not significant (rZK0.2,
Fig. 2). When the three diagnostic groups were
examined separately, the pure anxiety group, like
the normal subjects, showed a significant corre-
lation between systems. (Tables 2A and B, Fig. 3)
This normal relationship was lost in the depressed
subjects, whether examining pure depressed sub-
jects alone or those with a comorbid anxiety
disorders (Tables 2A and B). The normal linkage
between systems was disrupted in the pure
depressed group despite the fact that they showed
a normal GH response to clonidine (Cameron et al.,Table 2A Correlation coefficients of ln AUC ACTH
with ln AUC GH.
Group Correlation F P
All controls K0.425 9.49 0.0036
All patients K0.208 1.95 0.17
Pure anxiety K0.563 6.02 0.03




K0.205 0.66 0.432004), and normal ACTH response to the stressor
(Young et al., 2004). The linkage was also disrupted
in the comorbid group, which showed an exagger-
ated ACTH response to the TSST but a normal GH
response to clonidine. Because the time between
challenges varied among subjects, we examined
whether subjects whose challenges were more than
1 week apart demonstrated a loss of this corre-
lation. Subjects studied within 7 days (mean 4.6G
2.1 days (SD), nZ18) demonstrated a correlation of
0.555 (FZ7.12, pZ0.01) while subjects studied
more than 1 week apart (meanZ18.6G8.8 days,
nZ26) still demonstrated a correlation of 0.35,
which was significant at the trend level (FZ3.39,
pZ0.07).
We also examined whether there was a signifi-
cant relationship between AUC cortisol and AUC
GH. In no case examined (all subjects, all controls,
all patients or subgroup of patients) was a signifi-
cant correlation observed between ln AUC GH and
ln AUC cortisol. This absence of correlation
occurred despite a highly significant correlation of
AUC ACTH and AUC cortisol (rZ0.64, FZ58.45, pZ
0.0001). We also found no relationship between
baseline (pre-TSST) ln cortisol or ln ACTH and ln
AUC GH.Table 2B Correlation coefficients of ln AUC cortisol
with ln AUC GH.
Group Correlation F P
All controls K0.119 0.588 0.45
All patients K0.152 0.975 0.33
Pure anxiety K0.256 0.771 0.40




Figure 3 Scatter plot with regression line for the
relationship between ACTH response to the TSST and
GH response to clonidine in the pure anxiety subjects.
AUC have been log transformed prior to plotting to
normalize distribution of hormones. The patients with
social phobia are shown with open squares and panic
disorder subjects with filled squares. A significant
correlation was observed in the pure anxiety group.
Figure 2 Scatter plot of the relationship between ACTH
response to the TSST and GH response to clonidine in
depressed patients, pure (MDD, triangles) and comorbid
(squares). AUC have been log transformed prior to
plotting to normalize distribution of hormones. There is
no significant relationship in the depressed patient group.
Figure 1 Scatter plot with regression line for the
relationship between ACTH response to the TSST and
GH response to clonidine in control subjects. Males are
indicated by the open squares and females by the filled
squares. AUC have been log transformed prior to plotting
to normalize distribution of hormones. A significant
relationship was found in normal subjects.
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This study, examining challenges to two stress-
activated systems, demonstrated an inverse corre-
lation between clonidine stimulated GH secretion
and ACTH response to an emotional stressor in
normal subjects. To the extent that GH response to
clonidine reflects a2-noradrenergic receptor sensi-
tivity and thus tonic LC noradrenergic activity (see
Abelson et al., 2005 for a complete discussion) the
negative correlation suggests that the magnitude of
the ACTH response to the stressor is inversely
related to noradrenergic basal tonic activity.
Consequently, within normal subjects those indi-
viduals who show low tonic noradrenergic activity
and normal a2-noradrenergic receptor sensitivity
would demonstrate a larger GH response to cloni-
dine and a smaller ACTH response on the TSST
challenge compared with individuals with elevated
noradrenergic tone and the consequent a-noradren-
ergic receptor desensitization leading to smaller GH
response to clonidine. Furthermore, the latter
finding would be associated with larger ACTH stress
responses to the TSST challenge. Thus, reactivity to
a stressor is linked to average basal noradrenergic
activity, indicating that noradrenergic input may
E.A. Young et al.812contribute to the acute ACTH response to stress.
The fact that the two challenges were administered
more than 1 week apart supports the idea that the
linkage reflects stable characteristics of these
systems within individuals. The finding of a signifi-
cant relationship between systems confirms basic
animal studies demonstrating that these systems
are two arms of a coordinated central stress
response (Sved et al., 2002; Dunn and Berridge,
1990; Valentino et al., 1991).
Our data suggest that the normal inverse
relationship between systems observed in normal
subjects is maintained in anxiety disorders, even
though subjects with anxiety disorders as a group
show smaller responses to clonidine than normal
subjects. The blunted GH responses suggest nor-
adrenergic hyperactivity (Cameron et al., 2004),
and a preserved relationship with the HPA axis
would therefore predict abnormal sensitivity in this
system as well; but pure anxiety patients did not
show significantly elevated HPA responses to the
TSST (Young et al., 2004). However, this correlation
is within the group and thus only indicates that
those individuals with the most blunted GH
response to clonidine show the largest ACTH
response to the TSST, whether or not their response
is ‘normal’.
In major depression, in contrast to anxiety
disorders, the normal relationship between tonic
LC activity and HPA axis activation appears to be
altered. The relationship is disrupted in both the
comorbid group, which demonstrated an exagger-
ated ACTH response to the stressor, and the pure
depressed group, which demonstrated a normal
response to the stressor. If we assume that
depression is accompanied by normal LC activity
(as shown by a normal GH response to clonidine in
these depressed patients) but that the HPA axis is
overactive, then the dissociation of these two
systems in depression would be expected.
We were able to observe a significant relation-
ship between AUC GH and AUC ACTH but not AUC
GH and AUC cortisol, despite the strong correlation
between AUC cortisol and AUC ACTH. These data
suggest that other factors (such as adrenal sensi-
tivity to ACTH) may modulate the cortisol response
to the stressor that leads the cortisol response to be
less tightly correlated to central noradrenergic tone
than ACTH. It is also of note that our differences
among diagnostic groups in response to the TSST
were observed primarily with ACTH and no signifi-
cant differences were observed with cortisol
response. It may be that ACTH better reflects
acute dynamics of this system, which would be
modulated by LC/noradrenergic activity while
cortisol is responding over a longer time frame.One possible mechanistic explanation for the
dissociation of these systems in depression could
involve the role of cortisol. Since depression is
associated with increased basal cortisol, and
cortisol will inhibit LC activity (Mc Ewen, 1995;
Watanabe et al., 1995), it is possible that increased
cortisol will ‘correct’ (i.e. decrease) increased LC
activation that may occur transiently during
depression. In contrast, there is little evidence of
chronic hypercortisolemia in anxiety disorders, so
in this group the chronic activation of the LC would
not be restrained by cortisol. These findings suggest
that in depression, the CRH activation that drives
the HPA axis is not associated with activation of
brainstem CRH pathways regulating the LC.
Several studies have examined the relationship
between basal cortisol or post-dexamethasone
cortisol and a measure of noradrenergic activity
such as plasma MHPG. CSF NE or urinary metabolites
of norepinephrine and urinary free cortisol (Roy
et al., 1986, 1988; Rosenbaum et al., 1983; Rubin
et al., 1985; Maes et al., 1991; Wong et al., 2000).
In contrast to our findings, most have shown a
positive relationship between elevated cortisol and
measures of noradrenergic activation in patients
with melancholic depression. The inverse relation-
ships we found involved ACTH, not cortisol, and we
believe this reflects mechanisms of acute regulat-
ory control in an activation paradigm. Different
neural mechanisms are likely to be involved when
measuring basal activity using measures like corti-
sol that integrate activity over longer time frames.
The study of Coplan et al. (1995) examined the
MHPG and cortisol response to clonidine and found
correlations in normal subjects, which were not
found in a group with panic disorder. Whether the
use of a different challenge or a different anxiety
group (panic disorder) accounts for the difference
in findings between our study and their study is not
clear. Both of our challenges were stimulatory
while Coplan et al. were examining inhibition of
basal circadian cortisol activity, which may involve
different neural pathways than stress activated
cortisol secretion. We were examining relationships
across challenges, while Coplan et al. looked within
a single challenge. Finally, our challenge looked at
acute reactivity to stress in relationship to chronic
activation of noradrenergic systems, which may be
different than acute effects of clonidine on cortisol.
In conclusion, our data suggest a clear inverse
relationship between tonic activity of the LC
noradrenergic system and the ACTH response to a
stressor. This suggests that under normal circum-
stances, noradrenergic systems can influence the
magnitude of the HPA axis response to stress. This
relationship observed in normal subjects was
Interaction noradrenergic and HPA systems 813preserved in subjects with an anxiety disorders but
disrupted by major depression, even in subjects
with primary anxiety disorders that developed a
depressive episode. Consequently, in subjects with
major depression, HPA axis activation in response
to a stressor appears autonomous of noradrenergic
influence. The mechanism whereby depression may
disrupt this relationship is unknown. Because
insensitivity of the HPA axis to glucocorticoid
negative feedback is a frequent occurrence
(Young et al., 1991, 1993, 2000), while the
sequellae of increased cortisol have been found
on other systems in major depression. (Gold and
Chrousos, 1999), it is possible that elevated basal
cortisol of depression may restrain the noradren-
ergic system without adequately restraining the
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